{
  "docId": "019de076-928b-754c-8bda-49c7fed3154d",
  "docSlug": "58a8f830d3c9f9a6fedd64a0d2a10227",
  "documentTitle": "ATAI | Investor Presentation Deck | 34 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 34,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes a map of global disease burden and key product features.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-928b-754c-8bda-49c7fed3154d/31",
  "deckHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d",
  "deckJsonHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d.json",
  "deckAnchorHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. World Health Organization; 2. Anxiety and Depression Association of America (2021); 3. GlobalData (as of 6/1/2023) - All recent approvals by the FDA have been reformulations of long-standing antidepressant and benzodiazepine options",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f355f40a-dafd-4441-9aa5-16b4bfac0da7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.52,
        "y": 0.6
      },
      "kind": "image",
      "text": "Global disease burden map",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dffe4e7f-a55a-4c9a-915f-53e7d40b037c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.02,
        "y": 0.62
      },
      "kind": "list",
      "text": "Demonstrated rapid onset activity of anxiolytic activity (non-deuterated etifoxine approved in France); Review of ~14m prescriptions in France underscores the strong safety track record for etifoxine; Differentiated tolerability profile, with limited sedative, addictive and/or cognitive impairing properties, unlike benzodiazepines",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "239c537a-ffae-427b-b8ff-24616bf5d94e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.27
      },
      "kind": "list",
      "text": "Anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time; 50% of US patients go untreated as a result of sub-optimal treatment options; No FDA approved novel treatments over the past decade",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51f2e229-0566-4afc-8fd7-515b329f97a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.8,
        "y": 0.6
      },
      "kind": "metric",
      "text": "~300m Anxiety disorder sufferers in 2019",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5eee58ca-b301-4a53-a950-367ed6f3852f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.8,
        "y": 0.75
      },
      "kind": "metric",
      "text": "#1 Most common mental health disorder",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae38a96e-b329-4005-87e8-b569e8454600",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.02,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Designed to have rapid onset of anxiolytic activity but without the negative side effects seen with benzodiazepines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d3cefd2-684e-40fb-a084-31dcc812af67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.02,
        "y": 0.19
      },
      "kind": "table",
      "text": "PRODUCT: Deuterated etifoxine HCl oral dosage form (GRX-917); INDICATIONS: Lead: Anxiety Disorders (e.g., GAD, SAD, PTSD, etc.); INTELLECTUAL PROPERTY: Issued composition of matter on deuterated etifoxine (GRX-917) and corresponding methods of use; CURRENT STATUS: Phase 1 trial completed in H2'22. Exploring partnership and external funding opportunities",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6da070e2-96e6-4e52-8ddc-ca9f1940abcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "Product Overview: GRX-917 for Anxiety Disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca79c7e0-edb9-448a-b6f9-2116e1e55373",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8b85a575-31d8-47a3-b939-fc55a6e2312c",
      "evidence": "The components of this slide, such as the use of a clear headline, bullet points, and a big number metric, align with the AIDA model's structure, which aims to grab attention, generate interest, create desire, and encourage action.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c65cfc1b-596e-44b3-abf6-776a6539dcbf",
      "evidence": "The deck emphasizes the need for effective treatments",
      "position": 0,
      "objective": "Highlight the importance of addressing mental health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7657d45c-02c7-40ab-9afc-a644dc2ed2c5",
      "evidence": "The deck follows a structure that aligns with the Golden Circle",
      "position": 1,
      "objective": "Explain the company's approach and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}